4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.
“In the past, intravitreal approaches for sustained delivery via a genetic medicine proved challenging in DME,” Carlos Quezada-Ruiz, MD, FASRS, senior vice president, therapeutic area head, ophthalmology at 4DMT, told Healio. “Today, results from SPECTRA highlight that 4D-150 can potentially help us fulfill our mission to help as many people afflicted with DME see and live better